Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Moderna Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $21.1B | |
|---|---|---|
| Revenue (ttm) | 2.2B | |
| Net income (ttm) | -3.2B | |
| EPS (ttm) | -$8.01 | |
| Shares out | 399.2M | |
| Volume | 10,987,308 | |
| Beta | 1.09 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.74B | $18.88B | $6.75B | $3.20B | $1.92B | -42.6% |
| Gross profit | $15.12B | $13.46B | $2.06B | $1.74B | $1.05B | -48.6% |
| Operating income | $13.30B | $9.42B | $-4.24B | $-3.58B | $-2.76B | — |
| Net income | $12.20B | $8.36B | $-4.71B | $-3.56B | $-2.82B | — |
| EPS (diluted) | $28.29 | $20.12 | $-12.33 | $-9.28 | — | — |
| EBITDA | $13.53B | $9.77B | $-3.62B | $-3.39B | $-2.54B | — |
| R&D | $1.99B | $3.30B | $4.85B | $4.54B | $3.13B | +12.0% |
| SG&A | $567.0M | $1.13B | $1.55B | $1.17B | $1.02B | +15.8% |
Recent company headlines from major financial publishers.
The mRNA platform's speed and adaptability result in best-in-class efficacy for multiple latent virus and oncology targets. MRNA establishes a broad, highly profitable commercial portfolio, driving revenues back toward $10B+ with 70%+ gross margins and substantial operating leverage.
Moderna undergoes a high-risk transition, absorbing multi-billion dollar operating losses to sustain its $3.1B R&D engine. The validated mRNA platform produces sufficient new blockbusters to return to revenue growth and reach steady-state profitability by the end of the decade.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.5% | $68.8 | $75.7 | $84.0 | $94.5 | $102 |
| 8.5% | $58.3 | $63.1 | $68.8 | $75.7 | $84.0 |
| 9.5% | $50.6 | $54.2 | $58.3 | $63.1 | $68.8 |
| 10.5% | $44.6 | $47.4 | $50.6 | $54.2 | $58.3 |
| 11.5% | $40.0 | $42.2 | $44.6 | $47.4 | $50.6 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
